Zobrazeno 1 - 10
of 63
pro vyhledávání: '"Stephen Frytak"'
Autor:
Robert L. Foote, Stephen Frytak, Ronald C. Petersen, Jeff A. Sloan, Paul L. Schaefer, Aminah Jatoi, S. P. Kahanic
Publikováno v:
Supportive Care in Cancer. 13:66-69
Up to 90% of small cell lung cancer (SCLC) patients suffer cognitive dysfunction. Since donepezil and vitamin E have been somewhat successful in treating other dementias, this study tested the hypothesis that these agents can prevent cognitive declin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b76c1f021b6707f69c75165bda1608ed
https://doi.org/10.1007/s00520-004-0696-0
https://doi.org/10.1007/s00520-004-0696-0
Autor:
Joseph Rubin, Prema P. Peethambaram, Bradley Lewis, Stephen Frytak, Evanthia Galanis, Catherine Spier, Scott H. Okuno, Emmanuel T. Akporiaye, Patrick A. Burch, Henry C. Pitot, Judith S. Kaur, Ronald L. Richardson, K. Krishnan Unni
Publikováno v:
Cancer. 101:2557-2566
BACKGROUND Leuvectin (Vical Inc., San Diego, CA) is a gene transfer product in which a plasmid encoding the human interleukin-2 (IL-2) gene is complexed with the cationic lipid 1,2-dimyristyloxypropyl-3-dimethylhydroxyethyl ammonium bromide/dioleoylp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a4ad94c4a4b49560839e586a852ccfd1
https://doi.org/10.1002/cncr.20653
https://doi.org/10.1002/cncr.20653
Autor:
Stephen Frytak, M B S Carla Lange, Peter C. Pairolero, Victor F. Trastek, Mark S. Allen, Timothy E. Sawyer, James A. Bonner, Robert L. Foote, Claude Deschamps, Perry M. Gould, Hongzhe Li, Edward G. Shaw, Randolph S. Marks
Publikováno v:
Cancer. 80:1399-1408
BACKGROUND Previous nonsmall cell lung carcinoma studies have shown that patients with ipsilateral mediastinal (N2) lymph node involvement who underwent surgical resection have a greater local recurrence rate than those with less lymph node involveme
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1f218bedd10e56dbadd37912f60fa46c
https://doi.org/10.1002/(sici)1097-0142(19971015)80:8<1399::aid-cncr6>3.0.co
https://doi.org/10.1002/(sici)1097-0142(19971015)80:8<1399::aid-cncr6>3.0.co
Publikováno v:
American Journal of Clinical Oncology. 20:500-504
Cisplatin and carboplatin are platinum-based chemotherapeutic agents with broad antitumor activity and significantly different toxicity profiles. They are commonly used in combination with etoposide (VP-16) in chemotherapeutic regimens. We conducted
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6df001cfb89d0288bb67bf4a82d229c6
https://doi.org/10.1097/00000421-199710000-00013
https://doi.org/10.1097/00000421-199710000-00013
Autor:
Daniel J. Schaid, Edward G. Shaw, Robert T. Eagan, Robert L. Foote, John Q. Su, Stephen Frytak, Robert E. Lee, Ronald L. Richardson, Edward T. Creagan, James R. Jett
Publikováno v:
American Journal of Clinical Oncology. 19:154-158
Our purpose was to determine the ability of an etoposide-cisplatin (EP )-based regimen to salvage patients with limited and extensive small-cell lung cancer who are incomplete responders to cyclophosphamide-Adriamycin-vincristine-etoposide (CAVE) che
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::060a4e53e536ec04e0ec23b45466ebfa
https://doi.org/10.1097/00000421-199604000-00013
https://doi.org/10.1097/00000421-199604000-00013
Autor:
Robert T. Eagan, Edward G. Shaw, James A. Bonner, Ronald L. Richardson, Vichaivood Liengswangwong, Richard G. Evans, Stephen Frytak, Edward T. Creagan
Publikováno v:
Cancer. 76:406-412
Background. A Phase I/II study of an aggressive six-drug chemotherapy regimen followed by the use of sequential hemibody radiation therapy as a possible non-cross-resistant systemic treatment was undertaken for patients with extensive stage small cel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::72b8ab071af2eb09b5a42d7b98589689
https://doi.org/10.1002/1097-0142(19950801)76:3<406::aid-cncr2820760310>3.0.co
https://doi.org/10.1002/1097-0142(19950801)76:3<406::aid-cncr2820760310>3.0.co
Autor:
H. A. Homburger, T. G. Call, Stephen Frytak, Edward T. Creagan, Jerry A. Katzmann, Jan C. Buckner, C. Van Haelst-Pisani
Publikováno v:
American Journal of Clinical Oncology. 17:344-347
A Phase I study of rIL-2 and levamisole was performed to evaluate the activity, toxicity, and effect on immune parameters of this combination of agents in patients with advanced malignancy. Twelve patients with advanced cancer were included and begun
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bbe3ac40464ef7372038e68d565956e9
https://doi.org/10.1097/00000421-199408000-00013
https://doi.org/10.1097/00000421-199408000-00013
Autor:
M. Shiraki, John S.J. Brooks, Louise Ryan, Ronald H. Blum, D. R. Parkinson, Stephen Frytak, John H. Edmonson
Publikováno v:
Journal of Clinical Oncology. 11:1269-1275
PURPOSE This three-armed phase III study in adults with advanced soft tissue sarcomas was planned as a comparison of objective regression rates, toxicity, and survival of patients receiving doxorubicin alone, ifosfamide plus doxorubicin, and mitomyci
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::441068ee49b0809cd97c5c0bba8fd76c
https://doi.org/10.1200/jco.1993.11.7.1269
https://doi.org/10.1200/jco.1993.11.7.1269
Autor:
James A. Bonner, Edward G. Shaw, John C. McDougall, James A. Martenson, Stephen Frytak, Claude Deschamps, Robert L. Foote
Publikováno v:
Mayo Clinic Proceedings. 68:593-602
Most patients who have lung cancer will receive radiation therapy at some point during the course of their disease. For patients with non-small-cell lung cancer, radiation therapy is sometimes used after complete resection, particularly in patients w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c99d7d2f00970c636b46db4de8acc3b9
https://doi.org/10.1016/s0025-6196(12)60375-9
https://doi.org/10.1016/s0025-6196(12)60375-9
Publikováno v:
American Journal of Clinical Oncology. 14:156-161
Twenty patients with histologically proven metastatic melanoma were scanned with a 99mtechnetium (99mTc)-labeled melanoma antibody to determine the detection rate of known malignant lesions and to evaluate the antibody's ability to discover occult me
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::10de5b45010f29532f7c528cee93e4cc
https://doi.org/10.1097/00000421-199104000-00012
https://doi.org/10.1097/00000421-199104000-00012